Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06674863 · ClinicalTrials.gov registry record · NA
Addressing Health Literacy With a Tailored Survivorship Care Plan
A NA study of Stage IVB Prostate Cancer AJCC v8 and Localized Prostate Carcinoma, sponsored by Emory University.
- Recruiting
- Registry status
- NA
- Development phase
- 150
- Enrollment target
- 3
- Study locations
NCT06674863 is a NA study of Stage IVB Prostate Cancer AJCC v8 and Localized Prostate Carcinoma that is actively recruiting participants, run by Emory University. The registered enrollment target is 150 participants, below the 174-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (14% lower). The trial reports 3 study locations across 1 state.
The verdict
NCT06674863, a NA study of Stage IVB Prostate Cancer AJCC v8 and Localized Prostate Carcinoma, is actively recruiting participants, sponsored by Emory University.
- RECRUITING
- Registry status
- NA
- Development phase
- 150 participants
- Enrollment target
- 3
- Study locations
Study Summary
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from where it first started (primary site) to a limited number of places in the body (oligometastatic). SCPs summarize treatment history and recommendations for monitoring and maintaining health, and may also include potential long term effects of treatments received. The intention of a SCP is to help patients participate in their own health care. However, many patients have below basic levels of health literacy, meaning, they have a lower ability to obtain, communicate, process and understand basic health information and services to make health decisions. In fact, poor health literacy has been linked with worse quality of life in prostate cancer survivors. A tailored SCP includes the addition of an educational supplement based on lower reading and writing skills (low literacy) and may address health literacy barriers to understanding of treatment options and side effects. A standard SCP uses a template based on the American Society of Clinical Oncology (ASCO) guidelines for prostate cancer. A tailored SCP with low literacy educational supplements may be more effective compared to a standard SCP in improving understanding and access to survivorship care in black or African American patients with localized or oligometastatic prostate cancer.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Supportive Care
- OTHER Educational Intervention
- OTHER Interview
Study Locations (3)
Georgia
- Grady Memorial Hospital - Atlanta
- Emory University Hospital/Winship Cancer Institute - Atlanta
- Atlanta VA Medical Center - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-11-07 |
| Est. Completion | 2030-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06674863
The ClinicalTrials.gov registry entry for NCT06674863 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 45 other Stage IVB Prostate Cancer AJCC v8 trials with a reported enrollment target (14% lower). The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Stage IVB Prostate Cancer AJCC v8 appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT06674863 reports 3 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06674863 about?
NCT06674863 is a clinical study titled "Addressing Health Literacy With a Tailored Survivorship Care Plan". This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to other parts of the body (localized) or that has spread from w...
What is the current status of trial NCT06674863?
This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-11-07. Estimated completion is 2030-12-31.
What conditions does trial NCT06674863 study?
This clinical trial studies the following conditions: Stage IVB Prostate Cancer AJCC v8, Localized Prostate Carcinoma, Oligometastatic Prostate Carcinoma.
What interventions are being tested in trial NCT06674863?
The interventions under investigation include: Questionnaire Administration (OTHER), Supportive Care (OTHER), Educational Intervention (OTHER), Interview (OTHER).
Who is sponsoring clinical trial NCT06674863?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06674863 being conducted?
This trial has 3 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IVB Prostate Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
RECRUITING
-
PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer
RECRUITING · Phase 1
-
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
RECRUITING · Phase 2
-
Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy
RECRUITING · Phase 1
-
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
RECRUITING · Phase 2
-
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.